LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Sonendo, Inc. (“Sonendo” or the “Company”) (OTCQX: SONX), a leading dental technology company and developer of the GentleWave® System, today reported financial results for the second quarter ended June 30, 2024.
Recent Highlights
“We are very encouraged by the early results of the strategic reset we embarked earlier this year,” said Bjarne Bergheim, President and Chief Executive Officer of Sonendo. “We are driving commercial discipline through a refined go-to-market strategy and we are exceeding our own timelines for delivering on gross margin expansion, all while dramatically reducing operating expenses and free cash flow burn through a leaner, more efficient organizational structure. Additionally, the increased reliability of the GentleWave® G4 System has improved the customer experience and enabled us to successfully re-engage our legacy customer base through upgrade programs while simultaneously expanding our new-customer base, both of which we expect to drive higher procedure instrument utilization and revenue in the long-term.”
Second Quarter 2024 Financial Results
Except as otherwise indicated, the GAAP and non-GAAP financial measures presented in this press release exclude discontinued operations associated with the Company’s divestiture of its TDO practice management software segment in March 2024.
Total revenue was $8.3 million for the second quarter of 2024, a 5% decrease compared to second quarter of 2023. GentleWave console revenue totaled $2.4 million, a 9% increase compared to the second quarter of 2023, which was comprised of 35 upgrades and a 13 unit increase to the installed base. The Company’s installed base totaled 1,155 as of June 30, 2024. Procedure instrument revenue totaled $4.7 million, a decrease compared to $5.6 million for the prior year quarter. Other product revenue totaled $1.2 million for the second quarter of 2024, a $0.2 million year-over-year increase.
GAAP gross margin for the second quarter of 2024 increased to 37.5%, compared to a negative gross margin of 5.5% for the second quarter of 2023. During the second quarter of 2024 and 2023, respectively, the Company recorded in cost of sales $0.2 million and $2.9 million in excess and obsolete inventory charges related to recently discontinued products. Adjusted gross margin (non-GAAP) for the second quarter of 2024 was 40.7% compared to 28.7% for the prior year quarter.
Total operating expenses for the second quarter of 2024 totaled $9.8 million, a $7.1 million reduction compared to the prior year period.
Operating loss totaled $6.7 million for the second quarter of 2024, a $10.7 million reduction compared to the prior year quarter. Adjusted EBITDA (non-GAAP) loss totaled $5.7 million, a $6.9 million reduction compared to the prior year period.
Net loss from continuing operations totaled $7.4 million for the second quarter of 2024, a $10.7 million reduction compared to the prior year quarter.
Free cash flow burn (non-GAAP), which the Company defines as the sum of net cash used in operating activities and purchases of property and equipment, totaled $(6.7) million for the second quarter of 2024, a $3.0 million improvement compared to the prior year quarter.
As of June 30, 2024, the Company’s cash and cash equivalents and short-term investments totaled $24.2 million, and there were $20.5 million of principal payments outstanding under its term loan facility.
2024 Financial Guidance
For the full year 2024, the Company is increasing its expectations for total revenue from continuing operations to be in the range of $31 to $32 million, compared to previous guidance of $29 to $31 million.
Webcast and Conference Call Information
Sonendo will host a conference call to discuss the second quarter 2024 financial results after the market close on Wednesday, August 7, 2024, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing (833) 470-1428 for domestic callers or (404) 975-4839 for international callers, using access code: 699662. Live audio of the webcast will be available at: https://investor.sonendo.com. An archived recording will be available on the “Investors” section of the Company’s website for replay for at least 30 days after the event.
About Sonendo
Sonendo is a commercial-stage medical technology Company focused on saving teeth from tooth decay, the most prevalent chronic disease globally. Sonendo develops and manufactures the GentleWave® System, an innovative technology platform designed to treat tooth decay by cleaning and disinfecting the microscopic spaces within teeth without the need to remove tooth structure. The system utilizes a proprietary mechanism of action, which combines procedure fluid optimization, broad-spectrum acoustic energy and advanced fluid dynamics, to debride and disinfect deep regions of the complex root canal system in a less invasive procedure that preserves tooth structure. The clinical benefits of the GentleWave System when compared to conventional methods of root canal therapy include improved clinical outcomes, such as superior cleaning that is independent of root canal complexity and tooth anatomy, high and rapid rates of healing and minimal to no post-operative pain. In addition, the GentleWave System can improve the workflow and economics of dental practices.
For more information about Sonendo and the GentleWave System, please visit www.sonendo.com. To find a GentleWave doctor in your area, please visit www.gentlewave.com.
Forward Looking Statements
This press release includes forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, express or implied forward-looking statements relating to the Company’s anticipated business and financial performance on an on-going basis and Sonendo’s 2024 financial guidance. You are cautioned that such statements are not guarantees of future performance and that our actual results may differ materially from those set forth in the forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions; speak only as of the date they are made; and, as a result, are subject to risks and uncertainties that may change at any time. Factors that could cause the Company’s actual results to differ materially from these forward-looking statements are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission, including the “Risk Factors” set forth in our Annual Report on Form 10-K, as supplemented by our quarterly reports on Form 10-Q. Such filings are available on our website or at www.sec.gov. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent developments, events, or circumstances, except as may be required under applicable securities laws. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.
Use of Non-GAAP Financial Measures
Sonendo’s financial results are prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”). In this press release, the Company also presents various non-GAAP financial measures, including adjusted gross margin, adjusted EBITDA loss and free cash flow burn (collectively, the “Non-GAAP” measures). The Company recently revised its methodology for calculating the Non-GAAP Measures. The following tables present reconciliations of various financial measures calculated in accordance with GAAP to those Non-GAAP measures that exclude (or, in the case of free cash flow burn, include) items specified in the tables. The GAAP measures shown in the tables below represent the most comparable GAAP measure to the applicable non-GAAP measures shown in the table. For further information regarding the nature of these exclusions or inclusions, why the Company believes that these non-GAAP financial measures provide useful information to investors, the specific manner in which management uses these measures, and some of the limitations associated with the use of these measures, please refer to the Company’s Current Report on Form 8-K regarding this press release filed today with the SEC available on the SEC’s website at www.sec.gov and on the “Investors” page of the Company’s website at https://investor.sonendo.com.
|
SONENDO, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share data) |
||||||||
|
|
|
June 30, |
|
December 31, |
||||
|
|
|
2024 |
|
2023 |
||||
|
|
|
(Unaudited) |
|
|
||||
|
ASSETS |
|
|
|
|
||||
|
Current assets: |
|
|
|
|
||||
|
Cash and cash equivalents |
|
$ |
15,703 |
|
|
$ |
14,009 |
|
|
Short-term investments |
|
|
8,533 |
|
|
|
32,773 |
|
|
Accounts receivable, net |
|
|
4,528 |
|
|
|
4,790 |
|
|
Inventory |
|
|
11,798 |
|
|
|
11,074 |
|
|
Prepaid expenses and other current assets |
|
|
1,025 |
|
|
|
1,969 |
|
|
Current assets of discontinued operations |
|
|
927 |
|
|
|
656 |
|
|
Total current assets |
|
|
42,514 |
|
|
|
65,271 |
|
|
Property and equipment, net |
|
|
766 |
|
|
|
461 |
|
|
Operating lease right-of-use assets |
|
|
2,899 |
|
|
|
2,703 |
|
|
Other assets |
|
|
124 |
|
|
|
128 |
|
|
Non-current assets of discontinued operations |
|
|
— |
|
|
|
9,597 |
|
|
Total assets |
|
$ |
46,303 |
|
|
$ |
78,160 |
|
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
||||
|
Current liabilities: |
|
|
|
|
||||
|
Accounts payable |
|
$ |
931 |
|
|
$ |
1,142 |
|
|
Accrued expenses |
|
|
1,874 |
|
|
|
3,072 |
|
|
Accrued compensation |
|
|
1,550 |
|
|
|
2,413 |
|
|
Operating lease liabilities |
|
|
983 |
|
|
|
1,250 |
|
|
Current portion of term loan |
|
|
10,800 |
|
|
|
24,900 |
|
|
Other current liabilities |
|
|
1,592 |
|
|
|
1,844 |
|
|
Current liabilities of discontinued operations |
|
|
— |
|
|
|
700 |
|
|
Total current liabilities |
|
|
17,730 |
|
|
|
35,321 |
|
|
Operating lease liabilities, net of current |
|
|
1,765 |
|
|
|
1,423 |
|
|
Term loan, net of current |
|
|
8,511 |
|
|
|
12,467 |
|
|
Other liabilities |
|
|
428 |
|
|
|
530 |
|
|
Total liabilities |
|
|
28,434 |
|
|
|
49,741 |
|
|
Commitments and contingencies |
|
|
|
|
||||
|
Stockholders’ equity: |
|
|
|
|
||||
|
Preferred stock, $0.001 par value; authorized —10,000,000 shares; issued and outstanding – none |
|
|
— |
|
|
|
— |
|
|
Common stock, $0.001 par value; authorized — 500,000,000 shares; issued and outstanding— 72,834,586 shares as of June 30, 2024 and 63,547,467 shares as of December 31, 2023 |
|
|
73 |
|
|
|
64 |
|
|
Additional paid-in-capital |
|
|
461,938 |
|
|
|
458,357 |
|
|
Accumulated other comprehensive loss |
|
|
(2 |
) |
|
|
11 |
|
|
Accumulated deficit |
|
|
(444,140 |
) |
|
|
(430,013 |
) |
|
Total stockholders’ equity |
|
|
17,869 |
|
|
|
28,419 |
|
|
Total liabilities and stockholders’ equity |
|
$ |
46,303 |
|
|
$ |
78,160 |
|
|
SONENDO, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited) (In thousands, except share and per share data) |
||||||||||||||||
|
|
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
||||||||||||
|
|
|
2024 |
|
2023 |
|
2024 |
|
2023 |
||||||||
|
Revenue, net |
|
$ |
8,314 |
|
|
$ |
8,763 |
|
|
$ |
15,361 |
|
|
$ |
17,441 |
|
|
Cost of sales |
|
|
5,198 |
|
|
|
9,248 |
|
|
|
10,244 |
|
|
|
15,948 |
|
|
Gross profit (loss) |
|
|
3,116 |
|
|
|
(485 |
) |
|
|
5,117 |
|
|
|
1,493 |
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
||||||||
|
Selling and marketing |
|
|
4,072 |
|
|
|
7,693 |
|
|
|
9,216 |
|
|
|
15,674 |
|
|
General and administrative |
|
|
4,163 |
|
|
|
6,416 |
|
|
|
9,080 |
|
|
|
12,549 |
|
|
Research and development |
|
|
1,568 |
|
|
|
2,764 |
|
|
|
3,757 |
|
|
|
5,691 |
|
|
Total operating expenses |
|
|
9,803 |
|
|
|
16,873 |
|
|
|
22,053 |
|
|
|
33,914 |
|
|
Operating loss |
|
|
(6,687 |
) |
|
|
(17,358 |
) |
|
|
(16,936 |
) |
|
|
(32,421 |
) |
|
Other expense, net: |
|
|
|
|
|
|
|
|
||||||||
|
Interest and financing costs, net |
|
|
(759 |
) |
|
|
(739 |
) |
|
|
(2,699 |
) |
|
|
(1,318 |
) |
|
Loss before income tax expense |
|
|
(7,446 |
) |
|
|
(18,097 |
) |
|
|
(19,635 |
) |
|
|
(33,739 |
) |
|
Income tax expense |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
Loss from continuing operations, net of tax |
|
|
(7,446 |
) |
|
|
(18,097 |
) |
|
|
(19,635 |
) |
|
|
(33,739 |
) |
|
Income from discontinued operations, net of tax |
|
|
81 |
|
|
|
407 |
|
|
|
5,508 |
|
|
|
678 |
|
|
Net loss |
|
$ |
(7,365 |
) |
|
$ |
(17,690 |
) |
|
$ |
(14,127 |
) |
|
$ |
(33,061 |
) |
|
|
|
|
|
|
|
|
|
|
||||||||
|
Other comprehensive income (net of tax): |
|
|
|
|
|
|
|
|
||||||||
|
Unrealized (loss) gain on short-term investments |
|
|
(1 |
) |
|
|
(25 |
) |
|
|
(13 |
) |
|
|
31 |
|
|
Comprehensive loss |
|
$ |
(7,366 |
) |
|
$ |
(17,715 |
) |
|
$ |
(14,140 |
) |
|
$ |
(33,030 |
) |
|
Net loss per share from continuing operations – basic and diluted |
|
$ |
(0.08 |
) |
|
$ |
(0.19 |
) |
|
$ |
(0.21 |
) |
|
$ |
(0.36 |
) |
|
Net income per share from discontinued operations – basic and diluted |
|
$ |
— |
|
|
$ |
— |
|
|
$ |
0.06 |
|
|
$ |
0.01 |
|
|
Net loss per share – basic and diluted |
|
$ |
(0.08 |
) |
|
$ |
(0.19 |
) |
|
$ |
(0.15 |
) |
|
$ |
(0.35 |
) |
|
Weighted-average shares outstanding – basic and diluted |
|
|
95,429,233 |
|
|
|
93,684,289 |
|
|
|
95,085,847 |
|
|
|
93,538,676 |
|
|
SONENDO, INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (unaudited; in thousands; except percentage) |
||||||||||||||||
|
|
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
||||||||||||
|
|
|
2024 |
|
2023 |
|
2024 |
|
2023 |
||||||||
|
Gross profit (loss) |
|
$ |
3,116 |
|
|
$ |
(485 |
) |
|
$ |
5,117 |
|
|
$ |
1,493 |
|
|
Gross margin |
|
|
37.5 |
% |
|
|
(5.5 |
%) |
|
|
33.3 |
% |
|
|
8.6 |
% |
|
|
|
|
|
|
|
|
|
|
||||||||
|
Adjustments: |
|
|
|
|
|
|
|
|
||||||||
|
Excess and obsolete inventory reserve related to recently discontinued products |
|
|
241 |
|
|
|
2,917 |
|
|
|
241 |
|
|
|
2,917 |
|
|
Impairment of long-lived assets |
|
|
15 |
|
|
|
— |
|
|
|
161 |
|
|
|
— |
|
|
Stock-based compensation expense |
|
|
8 |
|
|
|
79 |
|
|
|
310 |
|
|
|
218 |
|
|
Adjusted gross profit |
|
$ |
3,380 |
|
|
$ |
2,511 |
|
|
$ |
5,829 |
|
|
$ |
4,628 |
|
|
Adjusted gross margin |
|
|
40.7 |
% |
|
|
28.7 |
% |
|
|
37.9 |
% |
|
|
26.5 |
% |
|
|
|
|
|
|
|
|
|
|
||||||||
|
Loss from continuing operations, net of tax |
|
$ |
(7,446 |
) |
|
$ |
(18,097 |
) |
|
$ |
(19,635 |
) |
|
$ |
(33,739 |
) |
|
Adjustments: |
|
|
|
|
|
|
|
|
||||||||
|
Interest and financing costs, net |
|
|
759 |
|
|
|
739 |
|
|
|
2,699 |
|
|
|
1,318 |
|
|
Depreciation and amortization |
|
|
73 |
|
|
|
397 |
|
|
|
128 |
|
|
|
750 |
|
|
Excess and obsolete inventory reserve related to recently discontinued products |
|
|
241 |
|
|
|
2,917 |
|
|
|
241 |
|
|
|
2,917 |
|
|
Stock-based compensation expense |
|
|
635 |
|
|
|
1,422 |
|
|
|
2,433 |
|
|
|
2,766 |
|
|
Impairment of long-lived assets |
|
|
15 |
|
|
|
— |
|
|
|
161 |
|
|
|
— |
|
|
Adjusted EBITDA |
|
$ |
(5,723 |
) |
|
$ |
(12,622 |
) |
|
$ |
(13,973 |
) |
|
$ |
(25,988 |
) |
|
|
|
|
|
|
|
|
|
|
||||||||
|
Cash Flows |
|
|
|
|
|
|
|
|
||||||||
|
Cash flow used in operating activities |
|
$ |
(6,718 |
) |
|
$ |
(9,365 |
) |
|
$ |
(17,407 |
) |
|
$ |
(26,341 |
) |
|
Purchases of property and equipment |
|
|
(15 |
) |
|
|
(417 |
) |
|
|
(161 |
) |
|
|
(627 |
) |
|
Free cash flow (burn) |
|
$ |
(6,733 |
) |
|
$ |
(9,782 |
) |
|
$ |
(17,568 |
) |
|
$ |
(26,968 |
) |
Contacts
Investor Contact:
Gilmartin Group
Greg Chodaczek
IR@Sonendo.com
PALO ALTO, Calif., Nov. 22, 2024 /PRNewswire/ -- Aulisa® Medical USA, Inc., a leader in…
NEW YORK, Nov. 22, 2024 /PRNewswire/ -- Report on how AI is redefining market landscape -…
Vancouver, British Columbia--(Newsfile Corp. - November 22, 2024) - DEFENCE THERAPEUTICS INC. (CSE: DTC) (OTCQB:…
3,250 InsuJet Starter Packs Being Delivered to Pharmacies Across CanadaToronto, Ontario--(Newsfile Corp. - November 22,…
The new app allows users to browse services, book IV therapy, manage appointments, purchase packages,…
PHILADELPHIA, Nov. 22, 2024 /PRNewswire/ -- Independence Blue Cross (IBX) is implementing the Epic Payer Platform…